NCT04657224CompletedPhase 1
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Source: EU CTIS (euclinicaltrials.eu) · Last updated 26 Aug 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- First submitted
- 17 Jul 2024
- Start date
- 16 Feb 2021
- Lead sponsor
- Janssen Cilag International
- EU CT number
- 2024-512687-66-00
- EudraCT number
- 2020-003149-12
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 33
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Ziekenhuis Gent Coordinator of this site? Confirm its status | Gent | Belgium | Completed |
| Pratia S.A. Coordinator of this site? Confirm its status | Cracow | Poland | Completed |
| Pratia Hematologia Sp. Z o. o Coordinator of this site? Confirm its status | Katowice | Poland | Completed |
| Pratia S.A. Coordinator of this site? Confirm its status | Skorzewo | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.